Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation

JACC: Cardiovascular Interventions

Volumn 10, Issue 12, 2017, Pages 1189-1198

  Nakamura, Masato ^a   Iijima, Raisuke ^a   Ako, Junya ^b   Shinke, Toshiro ^c,s   Okada, Hisayuki ^d,s   Ito, Yoshiaki ^e,s   Ando, Kenji ^f,s   Anzai, Hitoshi ^g,s   Tanaka, Hiroyuki ^h,s   Ueda, Yasunori ^i,s   Takiuchi, Shin ^j,s   Nishida, Yasunori ^k,s   Ohira, Hiroshi ^l,s   Kawaguchi, Katsuhiro ^m,s   Kadotani, Makoto ^n,s   Niinuma, Hiroyuki ^o,s   Omiya, Kazuto ^p,s   Morita, Takashi ^q,s   Zen, Kan ^r,s   Yasaka, Yoshinori ^s   Inoue, Kenji ^s,t   Ishiwata, Sugao ^s,u   Ochiai, Masahiko ^s,v   Hamasaki, Toshimitsu ^w   Yokoi, Hiroyoshi ^s,x   Hara, Hidehiko ^s   Yaita, Yoshinori ^s   Takamisawa, Itaru ^s   Yajima, Junji ^s   Ishihara, Takayuki ^s   Nakamura, Shigeru ^s   Fujii, Kenshi ^s   Ashida, Kazuhiro ^s   Ota, Hiroshi ^s   Okutsu, Masaaki ^s   Oshima, Masao ^s   Kongoji, Ken ^s   Jinno, Yasushi ^s   Shutta, Ryu ^s   Shiode, Nobuo ^s   Oumi, Tetsuo ^s   Doijiri, Tatsuki ^s   Yokoi, Yoshiaki ^s   Ogawa, Takayuki ^s   Kimura, Keizo ^s   Munemasa, Mitsuru ^s   Mukawa, Hiroaki ^s   Komiyama, Kota ^s   Suzuki, Takeshi ^s   Inoue, Takumi ^s   Ueno, Takafumi ^s   Sugano, Teruyasu ^s   Yamashita, Jun ^s   Yasumura, Yoshio ^s   Kamiya, Haruo ^s   Fujita, Hiroshi ^s   Urasawa, Kazushi ^s   Ono, Shiro ^s   Ajioka, Masayoshi ^s   Ando, Jiro ^s   Mizuno, Koichi ^s   Hirayama, Haruo ^s   Tojo, Taiki ^s   Maekawa, Yuichiro ^s   Kawasaki, Tomohiro ^s   Okamura, Takayuki ^s   Toyota, Fumitoshi ^s   Hikichi, Yutaka ^s   Michishita, Ichiro ^s   Yagi, Takafumi ^s   Kamihata, Hiroshi ^s   Shindo, Naohisa ^s   Ishizaka, Nobukazu ^s   Ashikaga, Takashi ^s   Ozaki, Yukio ^s   Hara, Hisao ^s   Sakamoto, Hiroshi ^s   Kada, Kenji ^s   Doi, Naofumi ^s   Honye, Junko ^s   Takano, Hitoshi ^s   Kawata, Masahito ^s   Houzawa, Hidenori ^s   Ozawa, Toru ^s   Kikuchi, Arifumi ^s   Kadota, Kazushige ^s   Kijima, Yoichi ^s   Ikemoto, Tomokazu ^s   Shimada, Yoshihisa ^s   Yumoto, Kazuhiko ^s   Kawajiri, Kenji ^s   Nozaki, Yoichi ^s   Sakakibara, Masayoshi ^s   Tosaka, Atsushi ^s   Noma, Shigetaka ^s   Wakabayashi, Yasushi ^s   Okada, Masaharu ^s   Hirose, Mizuki ^s   Takagi, Yuichiro ^s   Takagi, Takuro ^s   Miyauchi, Katsumi ^s   Misu, Kazuhiko ^s   Yasuda, Satoshi ^s   Yoshikawa, Ryohei ^s   Inoue, Ichiro ^s   Yoshiyama, Minoru ^s   Masuyama, Toru ^s   Tomobuchi, Yoshiaki ^s   Yamazaki, Seiji ^s   Tanabe, Kengo ^s   Wagatsuma, Kenji ^s   Kato, Masayuki ^s   Kawai, Kazuya ^s   Hamazaki, Yuji ^s   Yamagishi, Masakazu ^s   Shibata, Yoshisato ^s   Watanabe, Kouki ^s   Tachibana, Koichi ^s   Wada, Hiroshi ^s   Ninomiya, Kenji ^s   Suzuki, Hiroshi ^s   Yoshioka, Jiro ^s   Mori, Chikara ^s   Sonoda, Masahiro ^s   Kataoka, Toru ^s   Terai, Hidenobu ^s   Onishi, Yuko ^s   Toma, Masanao ^s   Serikawa, Takeshi ^s   Otsuka, Yoritaka ^s   Yano, Shoji ^s   Ebisawa, Soichiro ^s   Takashima, Hiroaki ^s   Shimomura, Hideki ^s   Kurumatani, Yoko ^s   Sonoda, Shinjo ^s   Uehara, Hiroki ^s   more..

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^e SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^f KOKURA MEMORIAL HOSPITAL   (Japan)

^g Fuji Heavy Industries Health Insurance Corporation Ota General Hospital   (Japan)

^h TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j Higashi Takarazuka Satoh Hospital   (Japan)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l Edogawa Hospital   (Japan)

^m KOMAKI CITY HOSPITAL   (Japan)

ⁿ Kakogawa City Hospital   (Japan)

^o ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^p ST MARIANNA UNIVERSITY   (Japan)

^q OSAKA GENERAL MEDICAL CENTER   (Japan)

^r Omihachiman Community Medical Center   (Japan)

^s Hyogo Brain and Heart Center ^*

^t JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^u TORANOMON HOSPITAL   (Japan)

^v SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^w NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^x FUKUOKA SANNO HOSPITAL   (Japan)

more..

Author keywords

biodegradable polymer; drug eluting stent(s); dual antiplatelet therapy; net adverse clinical and cerebrovascular event(s); stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; POLYMER; TICLOPIDINE; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BIODEGRADABLE IMPLANT; BLEEDING; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ELUTING CORONARY STENT; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; DEVICES; DRUG ADMINISTRATION; DRUG ELUTING STENT; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; AGED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; INTENTION TO TREAT ANALYSIS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMERS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85020865128     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2017.04.019     Document Type: Article

References (25)

1. Iakovou, I., Schmidt, T., Bonizzoni, E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005), 2126–2130.
2. Mauri, L., Hsieh, W.H., Massaro, J.M., Ho, K.K., D'Agostino, R., Cutlip, D.E., Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007), 1020–1029.
3. Kimura, T., Morimoto, T., Nakagawa, Y., et al. Antiplatelet therapy and long-term clinical outcome after sirolimus-eluting stent implantation: 5-year outcome of the j-Cypher registry. Cardiovasc Interv Ther 27 (2012), 181–188.
4. Valgimigli, M., Campo, G., Monti, M., et al., Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
5. Schulz-Schüpke, S., Byrne, R.A., Ten Berg, J.M., et al., Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
6. Gilard, M., Barragan, P., Noryani, A.A., et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 65 (2015), 777–786.
7. Colombo, A., Chieffo, A., Frasheri, A., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
8. Gwon, H.C., Hahn, J.Y., Park, K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
9. Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
10. Stefanini, G.G., Byrne, R.A., Serruys, P.W., et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 33 (2012), 1214–1222.
11. Sabaté, M., Räber, L., Heg, D., et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. J Am Coll Cardiol Intv 7 (2014), 55–63.
12. O'Brien, P.C., Fleming, T.R., A multiple testing procedure for clinical trials. Biometrics 35 (1979), 549–556.
13. Lincoff, A.M., Bittl, J.A., Harrington, R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003), 853–863.
14. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
15. Cutlip, D.E., Windecker, S., Mehran, R., et al., Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
16. Natsuaki, M., Kozuma, K., Morimoto, T., et al. Final 3-year outcome of a randomized trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial. Circ Cardiovasc Interv, 8, 2015, e002817.
17. Han, Y., Xu, B., Xu, K., et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv, 9, 2016, e003145.
18. Noad, R.L., Hanratty, C.G., Walsh, S.J., Initial experience of bioabsorbable polymer everolimus-eluting synergy stents in high-risk patients undergoing complex percutaneous coronary intervention with early discontinuation of dual-antiplatelet therapy. J Invasive Cardiol 29 (2017), 36–41.
19. Giustino, G., Chieffo, A., Palmerini, T., et al. Efficacy and safety of dual antiplatelet therapy after Complex PCI. J Am Coll Cardiol 68 (2016), 1851–1864.
20. Spencer, F.A., Prasad, M., Vandvik, P.O., Chetan, D., Zhou, Q., Guyatt, G., Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 118–126.
21. Ko, D.T., Yun, L., Wijeysundera, H.C., et al. Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. Circ Cardiovasc Interv 3 (2010), 140–147.
22. Matteau, A., Yeh, R.W., Camenzind, E., et al. Balancing long-term risks of ischemic and bleeding complications after percutaneous coronary intervention with drug-eluting stents. Am J Cardiol 116 (2015), 686–693.
23. Généreux, P., Giustino, G., Witzenbichler, B., et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 66 (2015), 1036–1045.
24. Lai, K.C., Lam, S.K., Chu, K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002), 2033–2038.
25. Bhatt, D.L., Cryer, B.L., Contant, C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.